The influence of prophylactic factor VIII in severe haemophilia A

被引:15
|
作者
Gissel, M. [1 ]
Whelihan, M. F. [1 ]
Ferris, L. A. [1 ]
Mann, K. G. [1 ]
Rivard, G. E. [2 ]
Brummel-Ziedins, K. E. [1 ]
机构
[1] Univ Vermont, Dept Biochem, Colchester, VT USA
[2] Univ Montreal, CHU Ste Justine, Montreal, PQ, Canada
关键词
factor VIII; factor XIII; haemophilia; inhibitory antibody; prophylaxis; thrombin generation; RECOMBINANT FACTOR VIIA; BLOOD-COAGULATION; THROMBIN GENERATION; EXTRINSIC PATHWAY; PLASMA FACTOR; FACTOR-IX; HEMOSTASIS; INHIBITOR; MODEL;
D O I
10.1111/j.1365-2516.2011.02638.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haemophilia A individuals displaying a similar genetic defect have heterogeneous clinical phenotypes. Our objective was to evaluate the underlying effect of exogenous factor (f)VIII on tissue factor (Tf)-initiated blood coagulation in severe haemophilia utilizing both empirical and computational models. We investigated twenty-five clinically severe haemophilia A patients. All individuals were on fVIII prophylaxis and had not received fVIII from 0.25 to 4 days prior to phlebotomy. Coagulation was initiated by the addition of Tf to contact-pathway inhibited whole blood +/- an anti-fVIII antibody. Aliquots were quenched over 20 min and analyzed for thrombin generation and fibrin formation. Coagulation factor levels were obtained and used to computationally predict thrombin generation with fVIII set to either zero or its value at the time of the draw. As a result of prophylactic fVIII, at the time of the blood draw, the individuals had fVIII levels that ranged from <1% to 22%. Thrombin generation (maximum level and rate) in both empirical and computational systems increased as the level of fVIII increased. FXIII activation rates also increased as the fVIII level increased. Upon suppression of fVIII, thrombin generation became comparable in both systems. Plasma composition analysis showed a negative correlation between bleeding history and computational thrombin generation in the absence of fVIII. Residual prophylactic fVIII directly causes an increase in thrombin generation and fibrin cross-linking in individuals with clinically severe haemophilia A. The combination of each individuals coagulation factors (outside of fVIII) determine each individuals baseline thrombin potential and may affect bleeding risk.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 50 条
  • [31] Continuous infusion of recombinant porcine factor VIII for neurosurgical management of intracranial haemorrhage in a patient with severe haemophilia A with factor VIII inhibitor
    Ruan, Gordon J.
    Mao, Jimmy J.
    Sytsma, Terin T.
    Akogyeram, Ivy I.
    Wang, Yucai
    Ashrani, Aneel A.
    Pruthi, Rajiv K.
    HAEMOPHILIA, 2020, 26 (03) : E141 - E144
  • [32] Catalytic antibodies to factor VIII in haemophilia A
    Lacroix-Desmazes, S
    Kazatchkine, MD
    Kaveri, SV
    BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 : S31 - S34
  • [33] Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
    Oldenburg, Johannes
    Chambost, Herve
    Liu, Hai
    Hawes, Charles
    You, Xiaojun
    Yang, Xinqun
    Newman, Vanessa
    Robinson, Tara M.
    Hatswell, Anthony J.
    Hinds, David
    Santos, Sandra
    Ozelo, Margareth
    ADVANCES IN THERAPY, 2024, 41 (06) : 2267 - 2281
  • [34] A transient high titer inhibitor in a boy with severe haemophilia A treated with recombinant factor VIII
    Gottstein, S.
    Budde, U.
    Klamroth, R.
    HAMOSTASEOLOGIE, 2009, 29 : S61 - S61
  • [35] Some factor VIII exon 14 frameshift mutations cause moderately severe haemophilia A
    Nakaya, S
    Liu, ML
    Thompson, AR
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) : 977 - 982
  • [36] Recombinant Fusion Factor VIII-Fc Fusion Protein in Severe Haemophilia A Patients
    Le Quellec, Sandra
    HEMATOLOGIE, 2014, 20 (06): : 304 - 306
  • [37] Protein truncation test: Detection of severe haemophilia A mutation and analysis of factor VIII transcripts
    Maugard, C
    Tuffery, S
    Aguilar-Martinez, P
    Schved, JF
    Gris, JC
    Demaille, J
    Claustres, M
    HUMAN MUTATION, 1998, 11 (01) : 18 - 22
  • [38] EFFICACY AND FACTOR CONSUMPTION OF LONG-ACTING RECOMBINANT FACTOR VIII PRODUCTS FOR PROPHYLACTIC TREATMENT OF HAEMOPHILIA A: A SYSTEMATIC REVIEW
    Graf, L.
    Yan, S.
    Shen, M. -C.
    Balasa, V.
    HAEMOPHILIA, 2020, 26 : 96 - 96
  • [39] Sclerotherapy of esophageal varices in severe haemophilia a patient and factor VIII high titre inhibitor
    Szczepanik, A. B.
    Dabrowski, W. P.
    Szczepanik, A. M.
    Jaskowiak, W.
    Pielacinski, K.
    Misiak, A.
    HAEMOPHILIA, 2013, 19 : 73 - 74
  • [40] Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
    Megias-Vericat, J. E.
    Bonanad, S.
    Haya, S.
    Cid, A. R.
    Marques, M. R.
    Monte, E.
    Perez-Alenda, S.
    Bosch, P.
    Querol, F.
    Poveda, J. L.
    THROMBOSIS RESEARCH, 2019, 174 : 151 - 162